Enter your search

NEWS

Celnova Pharma Selected by Alnylam Pharmaceuticals for Exclusive Distribution Agreement in Colombia for GIVLAARI® (givosiran), the First-in-Class RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria (AHP)

− GIVLAARI is the First Therapy Proven to Prevent AHP Attacks – Bogota, Colombia, November 18th, 2020 – Celnova Pharma, a Latin American company focused in complex therapeutic areas, announced today that the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) for GIVLAARI® (givosiran), a first-in-class RNAi therapeutic for the treatment […]

Celnova Pharma Selected by Alnylam Pharmaceuticals for Exclusive Distribution Agreement in Argentina for ONPATTRO® (patisiran), the First-in-Class RNAi Therapeutic

Buenos Aires, Argentina, 4 November 2020 – Celnova Pharma, a Latin American company focused in complex therapeutic areas, today announced the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, for ONPATTRO®, a first-in-class RNAi therapeutic for the treatment of hATTR amyloidosis in adults with Stage 1 […]

CELNOVA PHARMA ANNOUNCES AVAILABILITY OF APOKINON® IN ARGENTINA

Celnova Pharma announced today that APOKINON® (apomorphine self-injection pen) to treat loss of control of body movements (on-off periods) in people with advanced Parkinson’s disease (PD) is available in every pharmacy in Argentina. APOKINON® is commercialized in Argentina under a new exclusive distribution agreement signed between Celnova Pharma y Laboratoire Aguettant from France. APOKINON® is […]

CELNOVA PHARMA ANNOUNCES DISTRIBUTION AGREEMENT FOR APOKINON®

Celnova Pharma today announced that it has entered into an exclusive distribution agreement with Laboratoire Aguettant of France to commercialize APOKINON® (apomorphine self-injection pen) in the Argentine market. APOKINON® will be part of Celnova Pharma’s growing Central Nervous System portfolio. Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization […]

Celnova announces market launch of LEVENOVA™ in Argentina

Celnova Pharma today announced that it has obtained the marketing authorization in Argentina for Levenova™ (Levetiracetam tablets, 500mg and 1000mg) from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Levenova™ is now available in pharmacies across the country. Levenova™ is part of Celnova Pharma’s growing Central Nervous System portfolio. “We are excited about […]

Celnova announces market launch of DANTROLEN™ in Argentina

Celnova Pharma today announced that it has launched DANTROLEN™ (dantrolene sodium) in Argentina, the only therapeutic option for patients suffering from malignant hyperthermia. The product has been released to market and is available directly from Celnova Pharma and through leading institutional distributors. DANTROLEN™ is commercialized in Argentina through an exclusive distribution agreement between Celnova Pharma […]

Celnova announces distribution agreement with Norgine

Celnova Pharma today announced that it has entered into an exclusive distribution agreement with SpePharm AG, a wholly owned subsidiary of Netherlands-based Norgine B.V., to commercialize DANTROLEN™ (dantrolene sodium) in the Argentine market. Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization and distribution in Argentina. “We are excited […]